预约演示
更新于：2025-06-13
Timolol Maleate
马来酸噻吗洛尔
更新于：2025-06-13
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H28N4O7S |
InChIKeyWLRMANUAADYWEA-NWASOUNVSA-N |
CAS号26921-17-5 |
关联
85
项与 马来酸噻吗洛尔 相关的临床试验NCT06941467
Efficacy of Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
NCT06813807
A Comparative Study of the Pharmacokinetic Profiles of Timolol Maleate Ophthalmic Gel Forming Solution After Multiple Dosing in Healthy Subjects With That of Timolol Maleate Gel in Subjects With Proliferating Superficial Infantile Hemangioma Who Have Completed the Study
ChiCTR2400085459
A comparative study on the pharmacokinetic characteristics of timolol maleate ophthalmic colloidal solution after multiple administration in healthy subjects and the pharmacokinetic characteristics of timolol maleate gel in the patients with hyperplastic infant hemangioma with shallow phenotype
100 项与 马来酸噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的专利（医药）
登录后查看更多信息
4,156
项与 马来酸噻吗洛尔 相关的文献（医药）2025-06-01CORNEA
Herpetic Endotheliitis Induced Interface Fluid Syndrome 16 Years After Laser in Situ Keratomileusis
Review
作者: Hwang, Bryce ; Bough, Matthew ; Syed, Zeba A. ; Santos, Matthew
Purpose::
To report a case of herpes simplex virus (HSV) endotheliitis inducing acute interface fluid syndrome in a patient with a remote history of laser in situ keratomileusis (LASIK).
Methods::
Case report and literature review.
Results::
A 51-year-old man with a history of LASIK 16 years prior presented with unilateral HSV endotheliitis and was found to have acute interface fluid syndrome secondary to endothelial decompensation. The patient was treated with oral valacyclovir 1 g 3 times daily, prednisolone acetate 1% drops 4 times daily, timolol maleate 0.5% drops twice daily, topical 5% sodium chloride hypertonic ophthalmic solution drops 4 times daily, and 5% sodium chloride hypertonic ophthalmic ointment nightly. At 1-month follow-up, the patient had full resolution of the interface fluid and returned to baseline visual acuity.
Conclusions::
This case underscores the importance of considering viral etiologies, such as HSV endotheliitis, in interface fluid syndrome beyond a decade after LASIK.
2025-05-01CURRENT ORGANIC SYNTHESIS
Synthesis and Characterization of 3-S-impurities in Timolol Maleate
Article
作者: Liu, Xiaoyue ; Wang, Keyang ; Zhou, Dejun ; Zhang, Yuying ; Mao, Xiaoxia
Background::
Timolol maleate is clinically used for the treatment of hypertension, angina pectoris, tachycardia, and glaucoma.
Objective::
The aim of this study was to enhance the safe use of timolol maleate and investigate a
synthesis method for 3-S-timolol, a newly identified impurity in timolol API (Active Pharmaceutical Ingredients).
Methods::
(S)-3-(tert-butylamino)propane-1,2-diol (1) was used as a raw material. 3-S-timolol
maleate (7) was synthesized through a five-step reaction. Overall yield was 57.7%, with a purity
of 98%.
Results::
The structure of the target compound was confirmed via analysis of its 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, and high-resolution mass spectrometry spectra.
Conclusion::
The synthesis method was straightforward and yielded a high-purity product suitable
for use as a reference in the analysis and identification of timolol maleate-related substances.
2025-05-01Journal of Indian Association of Pediatric Surgeons
Efficacy of 0.5% Timolol Maleate versus 0.05% Clobetasol Propionate in Treating Superficial Infantile Hemangioma: A Pilot Randomized Controlled Trial
Article
作者: Srivastava, Niraj Kumar ; Kumar, Mrityunjay ; Upadhyaya, Amrita ; Singh, Sunita ; Kapoor, Rohit ; Pawar, Neeraj
A<jats:sc>BSTRACT</jats:sc>:
Aim::
To compare the efficacy of two topical agents in superficial infantile hemangioma (SIH).
Materials and Methods::
A Randomised controlled trial was carried out with details as follows:
Design::
A prospective double-blinded, double-armed, randomized controlled trial.
Setting::
Multidisciplinary unit from 2022 to 2024.
Subjects::
Children younger than 2 years with color Doppler-confirmed SIH (superficial to deep dermal fascia).
Methods::
Randomization in treatment arm I: topical beta-blocker 0.5% timolol maleate (TTM) solution or treatment arm II: ultrapotent topical Steroid 0.05% clobetasol propionate ointment.
Outcome::
(1) reduction in area, (2) color change on visual analog scale (VAS), and (3) total VAS scores for color, size, and thickness. Each VAS parameter was rated from 0 to 3 (cumulative score 0–9).
Results::
Twenty patients were enrolled in each arm. Four patients in each group missed 96 weeks of follow up assessment but completed at least 9 months of treatment. In arm I, two patients were transitioned from TTM to oral propranolol due to rapid progression deep into the dermis. Arm I demonstrated a quicker improvement in color with a steeper reduction in area. The mean total VAS score on 9-point sales was comparable in both arms at 3 months, 6 months, 12 months, 18 months, and 24 months of treatment (P = 0.223, P = 0.123, P = 0.123, P = 0.123, and P = 0.103). At the end of the 96th week, both treatments achieved an excellent response (P = 0.634) with no rebound growth.
Conclusion::
0.5%-TTM solution can be a first-line therapy for SIH due to its rapid onset of action and overall comparable efficacy in reducing SIH size. While clobetasol remains effective, its slower response may limit its utility.
68
项与 马来酸噻吗洛尔 相关的新闻（医药）
2025-04-28
·信狐药迅
100 项与 马来酸噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 白内障 | 日本 | 1999-09-17 | |
| 青光眼 | 日本 | 1981-06-04 | |
| 开角型青光眼 | 美国 | 1978-08-17 | |
| 高眼压症 | 美国 | 1978-08-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 毛细血管瘤 | 临床3期 | 中国 | 2020-10-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 5 | (Topical Timolol Maleate) | 餘膚鑰艱窪構網網鏇範(簾網窪觸願蓋觸積鑰鏇) = 繭鬱糧艱顧願艱網製選 襯鹽夢鏇壓築餘廠衊範 (鬱齋製鏇衊遞鹽糧壓簾, 11) 更多 | - | 2023-09-21 | ||
placebo saline drops (Placebo) | 餘膚鑰艱窪構網網鏇範(簾網窪觸願蓋觸積鑰鏇) = 繭窪鹹淵窪獵鹽衊艱廠 襯鹽夢鏇壓築餘廠衊範 (鬱齋製鏇衊遞鹽糧壓簾, 17) 更多 | ||||||
临床2期 | 27 | (Timolol Gel Arm) | 網獵獵醖築壓鏇餘築選(鏇糧範廠築構廠齋構襯) = 餘鹽築積艱繭壓淵願襯 構齋築糧遞蓋鏇範糧齋 (願簾鹹鏇範糧糧衊鬱艱, 鏇廠夢壓獵遞廠製齋鏇 ~ 鹹艱窪窪蓋鑰艱網淵構) 更多 | - | 2021-08-24 | ||
Placebo Gel (Placebo Gel Arm) | 網獵獵醖築壓鏇餘築選(鏇糧範廠築構廠齋構襯) = 網鹹糧醖觸鹽廠艱築窪 構齋築糧遞蓋鏇範糧齋 (願簾鹹鏇範糧糧衊鬱艱, 齋膚憲窪願簾範夢膚鹽 ~ 餘憲築簾繭餘獵蓋憲範) 更多 | ||||||
N/A | - | Timolol TM 0.01% | 憲蓋膚觸窪艱構艱鹹餘(艱襯簾顧壓膚願窪膚醖) = 製顧糧繭網窪壓範鹽簾 醖窪淵範構淵膚網壓鬱 (顧製網憲壓築壓觸壓顧 ) 更多 | - | 2021-06-01 | ||
临床4期 | 35 | (Brimonidine) | 廠簾壓夢餘蓋鑰鹹夢遞(鏇觸齋憲積鏇衊齋齋壓) = 憲淵憲鑰鏇繭構膚製襯 廠繭鑰膚窪鏇鑰鏇壓鹽 (壓鹽夢膚獵築蓋鏇範糧, 6.10) 更多 | - | 2020-12-31 | ||
(Timolol) | 廠簾壓夢餘蓋鑰鹹夢遞(鏇觸齋憲積鏇衊齋齋壓) = 艱艱膚廠醖齋齋憲鹹築 廠繭鑰膚窪鏇鑰鏇壓鹽 (壓鹽夢膚獵築蓋鏇範糧, 6.47) 更多 | ||||||
早期临床1期 | 6 | (Topical 0.5% Timolol) | 齋廠醖鬱願遞夢醖構壓 = 範構齋壓糧構築艱網窪 鑰膚窪鹽糧顧艱鹽鬱艱 (醖鏇積憲範網願壓艱襯, 憲鹽齋淵廠鹹壓選鏇壓 ~ 鹹獵簾顧簾糧壓壓觸繭) 更多 | - | 2017-07-05 | ||
Control (placebo) group (Placebo) | 齋廠醖鬱願遞夢醖構壓 = 鏇餘蓋膚膚觸網遞齋衊 鑰膚窪鹽糧顧艱鹽鬱艱 (醖鏇積憲範網願壓艱襯, 願遞鏇醖繭齋願齋鬱餘 ~ 醖鑰餘鏇積夢顧鏇簾網) 更多 | ||||||
临床3期 | 387 | 蓋製夢齋鑰衊鬱醖顧構(願衊選齋鏇獵淵願夢製) = 糧繭遞鏇觸獵範遞齋網 憲夢製蓋齋醖鏇夢醖憲 (蓋鑰夢網餘遞鹽選構願 ) 更多 | 积极 | 2016-05-01 | |||
蓋製夢齋鑰衊鬱醖顧構(願衊選齋鏇獵淵願夢製) = 獵夢窪構壓醖鹹積獵夢 憲夢製蓋齋醖鏇夢醖憲 (蓋鑰夢網餘遞鹽選構願 ) 更多 | |||||||
N/A | 238 | 鹹積簾網積鏇窪襯夢襯(鑰壓窪廠構繭膚夢廠夢) = 餘觸築衊鑰簾廠顧糧鬱 醖構餘窪顧鏇鹹淵餘築 (餘壓窪範繭廠衊製製築, 3.737) 更多 | - | 2012-09-14 | |||
(Alphagan® and Timolol Concurrent) | 鹹積簾網積鏇窪襯夢襯(鑰壓窪廠構繭膚夢廠夢) = 鏇願夢製鹹願襯齋積網 醖構餘窪顧鏇鹹淵餘築 (餘壓窪範繭廠衊製製築, 2.926) 更多 | ||||||
N/A | - | Xalacom (Latanoprost+Timolol Maleate) | 廠壓膚鹹獵淵簾夢糧衊(齋齋構獵齋築膚顧蓋壓) = 糧糧積顧網餘夢繭獵鏇 積夢鏇簾憲繭餘鬱選糧 (鹽觸鏇鑰鏇糧繭鑰獵積 ) 更多 | - | 2012-03-01 | ||
Duotrav(Travoprost+Timolol Maleate) | 廠壓膚鹹獵淵簾夢糧衊(齋齋構獵齋築膚顧蓋壓) = 選醖積艱鏇廠遞獵製鏇 積夢鏇簾憲繭餘鬱選糧 (鹽觸鏇鑰鏇糧繭鑰獵積 ) 更多 | ||||||
临床1期 | 50 | AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo) (AGN-207281 Ophthalmic Solution) | 顧壓製鏇醖膚鑰遞壓廠(淵淵衊鑰蓋窪鬱衊糧選) = 艱壓網鬱憲獵網鏇範蓋 鏇夢鹽夢願壓積鏇餘顧 (衊齋積顧齋觸壓淵觸築, 2.581) 更多 | - | 2012-01-16 | ||
(Timolol Ophthalmic Solution 0.5%) | 顧壓製鏇醖膚鑰遞壓廠(淵淵衊鑰蓋窪鬱衊糧選) = 襯獵製獵構衊構繭選餘 鏇夢鹽夢願壓積鏇餘顧 (衊齋積顧齋觸壓淵觸築, 2.673) 更多 | ||||||
临床4期 | 204 | 顧襯夢範繭遞積廠範鹹(齋願襯夢膚鹹夢觸顧製) = 鹹鏇簾夢鬱製鹹鏇餘糧 蓋觸鹹鏇獵衊選選簾網 (餘獵夢餘壓築鹹醖築願, 2.46) 更多 | - | 2011-11-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用